XML 33 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (USD $)
In Thousands, except Share data, unless otherwise specified
 3 Months Ended 6 Months Ended 126 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2012
Costs and expenses:          
Research and development $ 322 $ 497 $ 744 $ 1,187 $ 42,329
Selling, general and administrative 823 1,207 1,807 2,719 41,163
Merger transaction costs             5,470
Restructuring expense, net             2,413
Loss on impairment of in-process research and development             6,000
Total costs and expenses 1,145 1,704 2,551 3,906 97,375
Loss from operations (1,145) (1,704) (2,551) (3,906) (97,375)
Gain on bargain purchase             25,282
Gain on assignment of patent rights    2,000    2,000 2,000
Interest and other income 1    1 1 2,027
Interest and other expense (2) (2) (3) (7) (442)
Income (loss) before income taxes (1,146) 294 (2,553) (1,912) (68,508)
Benefit from income taxes             2,281
Net income (loss) (1,146) 294 (2,553) (1,912) (66,227)
Less: Accretion of redeemable convertible preferred stock             (245)
Less: Deemed preferred stock dividend for additional common shares issuable under anti-dilution provisions             (781)
Net income (loss) available to common stockholders $ (1,146) $ 294 $ (2,553) $ (1,912) $ (67,253)
Net loss available to common stockholders per share:          
Basic $ (0.09) $ 0.03 $ (0.21) $ (0.20)  
Diluted $ (0.09) $ 0.03 $ (0.21) $ (0.20)  
Weighted average shares outstanding:          
Basic 12,166,301 10,129,328 12,166,301 9,477,206  
Diluted 12,166,301 10,250,178 12,166,301 9,477,206